Longactil (Chlorpromazine) is commonly used across therapeutic domains involving certain distressing symptoms, applied in contexts marked by increased discomfort or tension. It helps address symptom clusters that may become intense or disruptive, especially in conditions characterized by periods of heightened symptoms.

The primary therapeutic applications include supportive management of psychotic disorders like schizophrenia, the acute manic phase of bipolar disorder, and for managing severe agitation or aggressive behaviors in both adults and children. Non-psychiatric uses are also relevant for easing the noticeable physiological strain of severe nausea and vomiting and for supporting the management of intractable hiccups (singultus).

The medication generally provides support that helps ease the overall symptom burden, assisting with maintaining functional stability when symptoms become temporarily overwhelming.

“It is commonly used to help with challenging symptoms that interfere with daily comfort and require short-term symptomatic assistance.”

---

Quick Fact: Relief for Intractable Hiccups

Longactil may be part of symptomatic management for severe, persistent episodes of hiccups (singultus) that may be difficult to manage, contributing to improved comfort during these periods.

Regulatory References

1. U.S. National Library of Medicine (DailyMed) Drug Label

Who can and cannot use Longactil (Chlorpromazine)

The population eligibility for Longactil is strictly defined by regulatory authorities based on patient status, age, and existing health conditions.

Contraindications (Must Not Use): Use is contraindicated in patients with a known hypersensitivity to phenothiazines or any component of the medicine. It must not be used in individuals who are in a comatose state, experiencing circulatory collapse, or have bone marrow depression. Contraindications also apply when large amounts of central nervous system depressants have been recently consumed.

Age-Related Eligibility:

• Adults: Use is established for all labeled indications.
• Children: Approved for specific severe behavioral problems and psychiatric disorders in children aged 1 to 12 years. Use is not recommended in infants under six months of age unless potentially life-saving.
• Older Adults: The medicine is not approved for treating dementia-related psychosis due to an increased risk of death.

Conditional Use and Restrictions: Patients with hepatic impairment, renal impairment, or a history of seizure disorder require caution and careful evaluation. Use during pregnancy is not recommended unless essential, and use during lactation is generally contraindicated.

Longactil (chlorpromazine) can interact with many other medications, which may alter the effects of either drug or increase the risk of serious side effects. It is essential to inform your healthcare provider about all prescription and non-prescription drugs, herbal products, and supplements you are taking.

Medications with Increased Risk of Sedation

Concurrent use of Longactil with Central Nervous System (CNS) depressants can cause additive sedative effects, leading to excessive drowsiness, dizziness, and respiratory depression. This includes:

Category	Examples
Opioids/Analgesics	Morphine, Oxycodone
Anxiolytics/Sedatives	Benzodiazepines (e.g., Lorazepam, Diazepam), Barbiturates
Antihistamines	Diphenhydramine (Benadryl)
Alcohol	Must be strictly avoided

Other Significant Interactions

• Drugs that prolong the QT interval (e.g., Amiodarone, Quinidine, certain other antipsychotics) can increase the risk of serious, life-threatening heart rhythm abnormalities. This combination is often contraindicated.
• Anticholinergic drugs (found in some Parkinson's, bladder, or depression medications) can lead to enhanced side effects like dry mouth, constipation, and difficulty urinating.
• Antihypertensives (for high blood pressure) may have their blood pressure-lowering effect enhanced, increasing the risk of severe hypotension (low blood pressure).
• Antidiabetic agents may have their therapeutic effect antagonized by Longactil, potentially requiring an adjustment in diabetes medication dosage.

Longactil (chlorpromazine) is a first-generation antipsychotic that modulates multiple neurotransmitter systems in the central nervous system. Its pharmacological mechanism involves the occupation and inhibition of several key receptors, initiating signal suppression cascades that influence physiological processes within targeted pathways.

Dopamine Receptor Antagonism

This mechanistic domain involves the blockade of postsynaptic dopamine receptors, primarily the D2 subtype in subcortical brain regions. This action decreases excessive dopaminergic signaling associated with dysregulated processes. The physiological consequence is an influence on neural activity to modify central physiological responses.

Serotonin and Histamine Receptor Modulation

Longactil engages mechanisms related to serotonergic (5-HT2A) and histaminergic (H1) receptor antagonism. H1 blockade leads to central nervous system depression, and it attenuates the signaling output of other mediators.

alpha-Adrenergic and Cholinergic Pathway Effects

Simultaneously, the drug acts within domains involving alpha-1 adrenergic (alpha1) and muscarinic cholinergic receptors. alpha1-adrenergic blocking action can lead to vasodilation and changes in blood pressure. Anticholinergic activity modulates pathways influencing smooth muscle function, including those associated with the medullary vomiting center.

Longactil (chlorpromazine) is administered via oral (tablets, liquid), intramuscular (IM) injection, intravenous (IV) injection, or rectal (suppositories) routes, as prescribed by a healthcare professional.

Official Administration and Dosing

Population/Route	General Dosing Guidelines
Oral (Adults)	Treatment typically begins with a low dose (e.g., 25 mg three times daily or 75 mg at bedtime) and is gradually increased to the effective maintenance range (e.g., 75 mg to 300 mg daily), with some conditions requiring higher dosages. The dose may be reduced to the lowest effective maintenance level once control is achieved.
IM Injection	The initial dose is typically 25 mg. This may be repeated in one hour if necessary. Subsequent doses may be increased and given every 4 to 6 hours until symptoms are controlled.
IV Injection	Intravenous administration is reserved for specific uses like during surgery or for intractable hiccups. The solution must be diluted (e.g., to not exceed 1 mg/mL concentration) and administered slowly (e.g., 1 mg/minute in adults).

Special Procedural Requirements

Dosage adjustments are required for specific age groups. Elderly or debilitated patients must start on one-third to one-half the usual adult dose, and dosage increases must be more gradual. For children aged 1 to 12 years, dosing is based on body weight, with maximum daily doses ranging from 40 mg to 75 mg depending on age.

When discontinuing therapy, the dosage should be gradually decreased over time. If a dose is missed when taking the medicine on a regular schedule, the missed dose is typically taken as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose is skipped.

Research Evidence / Overview of Studies for Longactil

This section reviews the types of medical studies and research that have examined the uses of Longactil (chlorpromazine). The information here describes what researchers have studied and the patterns they reported, without offering any personal medical guidance or claims about individual effectiveness.

---

Evidence for Use in Schizophrenia and other Psychotic Disorders

Longactil was studied for managing symptoms related to schizophrenia and similar conditions. The research in this area includes short-term Randomized Controlled Trials (RCTs), as well as systematic reviews and meta-analyses that brought together findings from many different studies.

Studies used in research exploring how symptoms change over time primarily monitored outcomes capturing phases of heightened symptom activity, such as delusions or hallucinations, using standard rating scales. Adults experiencing acute episodes were the typical population included. Studies reported patterns where measurements of these symptoms were lower in the chlorpromazine groups over the short follow-up periods compared to people who received a placebo.

---

Evidence for Use in Acute Manic Type of Bipolar Illness

Longactil was evaluated in studies focusing on the acute treatment of the manic phase of Bipolar I disorder. These were primarily short-term RCTs that focused on conditions involving periods of heightened symptoms (mania). Researchers monitored outcomes describing episodic or acute changes in behavior and agitation, using specific rating scales for mania.

The research exploring short-term symptom changes generally data show patterns related to changes in symptom scores and behavior monitored during the study period. However, the overall body of high-quality evidence specific to this indication is limited when compared to the research available for newer treatment options.

---

Long-Term Studies and Follow-Up Data

Studies tracking the use of Longactil over intermediate or long-term periods are less common than short-term trials. The available research was observed in studies conducted during periods of increased symptom activity or during the initial phase of treatment.

There is limited information for long-term outcomes that look at whether reported changes in symptoms are maintained over many years. When studies have attempted to look at long-term results, sample sizes were small, and results apply only to the populations studied. Understanding the durability or persistence of any observed effects requires more extensive follow-up research than is currently available.

---

What is Still Uncertain About Longactil

Despite being studied for many years, the research on Longactil still has important gaps.

Long-term effects are not fully established across all indications. The main challenge is that evidence quality varies across studies, with many older trials having methodological limitations. Comparative evidence is lacking for many direct comparisons against newer treatments. Research does not determine whether an individual will respond similarly to the group patterns reported in the studies.

Key Studies & References

1. CHLORPROMAZINE oral - MSF Medical Guidelines (Used for context on global use/older drug status)
2. Psychosis and schizophrenia in adults: prevention and management (NICE Guideline CG178)
3. Label: CHLORPROMAZINE tablet - DailyMed (NIH/FDA Label Information)

How to Store and Dispose of Longactil?

Longactil (chlorpromazine) must be stored strictly according to official regulatory specifications to maintain its stability and effectiveness. The medication should be kept in its original, tightly closed container.

Storage Constraint	Requirement
Temperature	Store below 40 C (104 F), preferably between 15 C and 30 C (59 F and 86 F).
Protection	Protect from light, excess heat, and moisture. Do not freeze the oral solution or injection.
Safety	Keep the medication out of the sight and reach of children, storing it in a locked cabinet if the container is not child-resistant.

Disposal must be conducted according to local environmental regulations. Do not dispose of Longactil by flushing it down a toilet or pouring it down a drain unless specifically instructed to do so by a healthcare provider or governmental program.